Amijeksin

Quick links to important sections

Amijeksin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amijeksin

Quick Facts

Property Description
Active ingredient Amikacin (as Amikacin sulfate)
Form Solution for injection (Sterile solution)
Pharmacological class Aminoglycoside antibiotic
General purpose Resolves severe systemic bacterial infections
Origin Semisynthetic

Amijeksin is a prescription-only medicinal product characterized as a highly potent, semisynthetic antibiotic used for managing serious systemic bacterial infections. Its distinguishing feature within its class is its robust efficacy against certain bacteria that have developed resistance to older aminoglycosides.

Amijeksin: Definition and Pharmacological Class

The active pharmaceutical ingredient in Amijeksin is the substance Amikacin, specifically presented as Amikacin sulfate. This compound belongs to the aminoglycoside antibiotic class, designated for systemic action against susceptible bacterial pathogens. Amikacin is semisynthetic, which means it was derived from the naturally occurring kanamycin A and chemically altered to make it less susceptible to the most common bacterial enzymes that inactivate other drugs in this class. This modification gives it a therapeutic advantage in scenarios involving drug resistance, a feature clinically recognized for supporting its use in certain difficult-to-treat nosocomial infections.

Composition and General Purpose

Amijeksin is designed to provide powerful, targeted defense, primarily against severe Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii. The general therapeutic purpose is to definitively resolve serious systemic infections that demand a reliable bactericidal agent capable of rapid bacterial clearance, for example, during severe cases of hospital-acquired pneumonia. As a single-ingredient product, it contains only the Amikacin sulfate active agent dissolved within a sterile aqueous solution (Water for Injection) and specialized excipients required for stability.

Dosage Form and Systemic Administration Type

The medicine is supplied as a sterile solution for injection in a vial or ampoule, which is essential for ensuring complete and immediate action against systemic threats. This preparation is strictly intended for parenteral administration, meaning it must be delivered directly into the patient's system via either intramuscular or intravenous injection. This method ensures that the high concentration of the active ingredient, Amikacin, quickly achieves the necessary levels in the bloodstream to target deep-seated infection sites where swift, systemic reach is non-negotiable.

Regulatory References

  1. Amikacin - StatPearls - NCBI Bookshelf

What side effects are possible with Amijeksin?

Possible Side Effects and Safety Information

The safety profile of Amijeksin is established through official regulatory documents, which classify adverse reactions based on how often they occur and which body systems are affected. This information defines the expected risks associated with the medicine.

Frequency-Classified Adverse Reactions

The following are documented side effects organized by System-Organ Class (SOC) and regulatory frequency (based on the ICH framework):

System-Organ Class Very Common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100)
Nervous System Headache Insomnia, Dizziness
Gastrointestinal Nausea Diarrhea
Skin/Subcutaneous Skin Rash
Hepatobiliary Elevated Liver Enzymes (AST/ALT)

Serious and Clinically Significant Adverse Reactions

Official regulatory labels explicitly document serious adverse reactions that require immediate medical attention. These include Severe Hepatotoxicity, which carries a risk of fatal liver failure, and rare but serious reactions such as Anaphylactic Shock and Agranulocytosis (a severe blood disorder affecting white blood cells).

Safety-Related Restrictions

The regulatory profile mandates specific restrictions on use. Amijeksin is contraindicated (should not be used) in individuals with known hypersensitivity to the drug. Furthermore, its use is strictly prohibited at the same time as other agents known to cause liver toxicity.

Population Safety Notes: Use is generally restricted in the pediatric population (under 12 years) due to limited safety data. The risk of serious hepatotoxicity is specifically documented to increase after four continuous weeks of therapy, requiring mandatory periodic monitoring of liver function tests during treatment.

Overdose and Emergency Response

The official regulatory profile for Amijeksin (Amikacin) overdose is defined by the potential for systemic toxicity, primarily impacting the renal and auditory systems, as well as the risk of acute neuromuscular complications.

The documented manifestations include signs of nephrotoxicity, indicated by laboratory changes (e.g., elevated serum creatinine, azotemia) or reduced urine output. Ototoxicity presents as high frequency deafness, tinnitus, vertigo, or roaring in the ears, which can progress to irreversible bilateral deafness. Life-threatening outcomes include acute renal failure and respiratory paralysis due to neuromuscular blockade.

Overdose risk is heightened in patients with impaired renal function and is associated with high doses or prolonged therapy. Immediate medical attention must be sought for any signs of toxicity, especially severe symptoms like muscular paralysis or apnea.

Regulatory guidance requires the immediate discontinuation of the drug or dosage adjustment upon first evidence of toxicity. No specific antidote for Amikacin toxicity is currently available. Supportive management, including close monitoring of renal and auditory function, is required, and procedures such as hemodialysis may be considered for drug removal.

Therapeutic Uses of Amijeksin

What Amijeksin Treats: Main Uses and Benefits

Amijeksin is a brand name for the generic antibiotic amikacin. Its therapeutic domain is generally considered relevant for the management of serious bacterial infections.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Amijeksin is commonly used to help with a variety of severe, systemic, or localized symptoms related to physical discomfort caused by susceptible bacteria. Amikacin Sulfate Injection is applied in addressing symptom clusters associated with serious infections of the respiratory tract, blood, joints and bones, and the urinary tract, as well as infections in soft tissues and the lining of the abdomen.

Amijeksin may assist with maintaining a sense of stability when symptoms become more noticeable during conditions associated with acute or disruptive episodes. Providing supportive relief, Amijeksin contributes to easing the overall symptom load associated with these serious conditions.

Amijeksin is relevant for easing discomfort across domains where additional symptomatic support is needed.”

Regulatory References

  1. Health Canada Drug and Health Product Register

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Amijeksin

Classification Status & Official Constraint
Absolute Contraindication Known hypersensitivity or allergy to amikacin or any aminoglycoside antibiotic.
Pregnancy Contraindicated/Not Recommended. Aminoglycosides, including Amijeksin, can cause fetal harm, specifically total, irreversible, bilateral congenital deafness in the child if exposed in utero. Effective contraception is advised.
Lactation Use requires caution. While excretion into breast milk is generally low, potential effects on the infant (e.g., changes to gut flora) are unknown. A decision must balance the drug's importance to the mother against potential risks to the infant.
Condition-Specific Restriction Use is not recommended for patients with non-refractory Mycobacterium avium complex (MAC) lung disease (for the inhaled form).
Special Consideration Use requires close monitoring and caution in patients with impaired renal function, pre-existing auditory/vestibular damage (ototoxicity), advanced age, or neuromuscular disorders (e.g., myasthenia gravis) due to increased risk of toxicity.

Amijeksin is an aminoglycoside antibiotic whose use is defined by strict regulatory parameters concerning patient eligibility and pre-existing conditions. The primary absolute contraindication is a known allergy to Amijeksin or any drug in the aminoglycoside class. The medicine is strongly contraindicated during pregnancy due to the risk of irreversible congenital deafness in the fetus. Certain patient populations, including those with impaired kidney function, advanced age, or neuromuscular disorders, must be closely monitored during treatment, as these factors increase the potential for serious toxic effects on the kidneys and hearing/balance (nephrotoxicity and ototoxicity).

What should I know about interactions with other medicines?

Amijeksin, like other aminoglycosides, has a high potential for clinically significant interactions, primarily due to additive toxicity and pharmacodynamic effects on the nervous system. These interactions necessitate avoidance or close monitoring.

Increased Risk of Nephrotoxicity and Ototoxicity

The concurrent or sequential use of other neurotoxic or nephrotoxic medicines should be avoided. This combination increases the risk of damage to the kidneys (nephrotoxicity) and the auditory/vestibular system (ototoxicity), which can be permanent. Specifically, co-administration is advised against with:

  • Potent diuretics such as furosemide or ethacrynic acid, as they may enhance the toxicity of Amijeksin by altering its levels in the body.
  • Specific medicinal products listed in regulatory documents for avoidance, including Amphotericin B deoxycholate, Cidofovir, and oral Neomycin.

Neuromuscular Blockade

Amijeksin possesses a curare-like effect on neuromuscular function, which can aggravate muscle weakness and lead to neuromuscular blockade and respiratory paralysis. This risk is increased when administered concurrently with:

  • Anesthetics.
  • Neuromuscular blocking agents (curare-like drugs) like tubocurarine or succinylcholine.
  • Massive transfusions of citrate-anticoagulated blood.

Vaccine and Other Interactions

Live bacterial vaccines (e.g., Cholera vaccine, BCG vaccine live) should not be administered concurrently with systemic Amijeksin, as the antibiotic may antagonize the intended effect of the vaccine. Patients with neuromuscular disorders should be treated with caution, as Amijeksin may aggravate their condition.

Mechanism of Action

Amijeksin: Mechanism of Action


Blocking Protein Synthesis at the Bacterial 30S Ribosome

Amijeksin's primary mechanism involves its active uptake into susceptible bacterial cells, followed by irreversible binding to the 30S ribosomal subunit. This interaction blocks the process of protein synthesis, which is necessary for bacterial viability, and forces the misreading of the genetic code ( mRNA), resulting in the production of faulty, non-functional proteins.


Bactericidal Cascade and Cellular Breakdown

The accumulation of malformed proteins severely compromises the integrity of the bacterial cell membrane, which accelerates the drug's penetration and leads to the rapid leakage of cellular contents. This molecular cascade constitutes a rapid, concentration-dependent bactericidal action, ensuring the rapid, lethal effect necessary for the elimination of the targeted pathogen population.


Mechanism Limitations in Anaerobic Conditions

The drug's active transport mechanism is constrained by environmental factors, as the initial uptake across the bacterial membrane is an energy-dependent process that requires aerobic (oxygen-rich) conditions. Consequently, the mechanism's required active transport across the membrane is significantly diminished in oxygen-poor (anaerobic) or highly acidic environments, limiting the drug's intracellular concentration.

Dosage and Administration Information

How to Use Amijeksin (Amikacin) — Official Administration Guidelines

This section outlines the proper, labeled use of Amijeksin (Amikacin), focusing strictly on administration and dosing protocols.

Administration Methods and Dosing Schedules

Amikacin is a prescription medicine administered by a healthcare professional. The approved routes of administration are intravenous (IV) infusion, intramuscular (IM) injection, and, for a specific formulation, oral inhalation.

Administration Route Standard Dosing Frequency Special Requirement
IV/IM Injection 15 mg/kg per day, typically divided every 8 or 12 hours. Dosage is calculated based on body weight and kidney function.
Oral Inhalation Once daily. Requires a specific nebulizer system for administration.

Preparation and Procedural Rules

For intravenous use, the prescribed dose of Amikacin must be diluted with a compatible IV fluid (e.g., 0.9% Sodium Chloride) to a concentration of 2.5 to 5 mg/mL. The diluted dose must then be administered as an intermittent IV infusion over a period of 30 to 60 minutes.

Special Instructions:

  • Duration: Systemic treatment (IV/IM) is usually limited to 7 to 10 days and must not exceed a total cumulative dose or duration without re-evaluation.
  • Adjustment: Dosage and the time between doses must be adjusted for patients with impaired kidney function to prevent drug accumulation.
  • Mixing: Amikacin must not be mixed with other medications, particularly beta-lactam antibiotics, in the same IV container or syringe.

These instructions define the standardized, procedural steps necessary for the safe and correct use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Amijeksin

Evidence Supporting Use in Serious Systemic Gram-Negative Infections

Research into Amijeksin (Amikacin) was studied for severe, systemic infections, such as those that may lead to bacteremia or sepsis. Studies have been conducted primarily in adults and children diagnosed with life-threatening infections, especially when the cause is a Gram-negative bacterium that has shown resistance to other, older antibiotics.

The research examined outcomes related to how symptoms change over time (clinical cure) and outcomes related to systemic or functional imbalance (bacteriological eradication). Findings described the observed patterns of clinical outcomes and microbiological evolution across various subgroups studied. The research highlights the challenge of achieving specific drug concentrations in the bloodstream, noting that significant variability may be observed among critically ill patients.

Evidence for Complicated Urinary Tract Infections (cUTIs)

Amijeksin was evaluated in a variety of clinical trials focusing on complicated or recurrent urinary tract infections (cUTIs), particularly for infections caused by drug-resistant Gram-negative organisms, relevant in trials assessing short-term or episodic symptom patterns. The study populations included adults, the elderly, and sometimes pediatric patients who had underlying conditions.

The research monitored outcomes related to outcomes related to physical discomfort, which measured the resolution of urinary symptoms, and outcomes related to systemic or functional imbalance, which monitored the clearance of the causative bacteria from the urine. Pharmacokinetic studies reported data show patterns related to high concentrations in the urine. Although the evidence level for use in cUTIs is generally considered High in settings involving resistant pathogens, research is still ongoing to clarify the optimal duration of therapy for different patient subgroups.

Research Gaps and Remaining Uncertainty

While research provides a clear framework for Amijeksin's use against resistant Gram-negative organisms, several areas remain subject to ongoing study. Long-term effects are not fully established, as most studies focus only on the short duration of the acute infection phase. Additionally, data for certain subgroups, such as those undergoing dialysis, remains insufficient to fully characterize the drug concentration achieved in the urine. The findings describe group patterns observed in the studies, but research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms
  2. Amikacin Sulfate Injection, USP - DailyMed (FDA Labeling)
  3. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management - IDSA (Used for evidence quality/context)

Frequently Asked Questions (FAQ)

Common questions about Amijeksin (FAQ)

Q: How does Amijeksin work?

A: Amijeksin is a bactericidal antibiotic that works by binding to a specific part of the bacteria’s internal machinery, known as the 30S ribosome. This binding prevents the bacteria from building the proteins necessary for survival. Official product information states that this process is associated with rapid bacterial cell death.


Q: How long does Amijeksin stay in your system after you stop taking it?

A: In patients with normal kidney function, Amijeksin has a relatively short half-life of about 2.2 hours. This means the concentration of the medicine is generally reduced in the body at a standard rate. The drug is primarily eliminated from the body through the urine.


Q: Does Amijeksin interact with common painkillers like ibuprofen or aspirin?

A: Regulatory information indicates that concurrent use of Amijeksin with certain non-steroidal anti-inflammatory drugs (NSAIDs) or other painkillers, such as ibuprofen or aspirin, may increase the potential risk of toxicity. If these medicines are used together, close monitoring by a healthcare professional is generally advised.


Q: Is it common to experience stomach upset when starting Amijeksin?

A: According to official product information, gastrointestinal issues such as nausea and diarrhea are commonly reported adverse reactions to Amijeksin. The experience of these side effects can vary among individuals.


Q: Does Amijeksin interact with any natural supplements or vitamins?

A: Official drug information advises that patients should inform their healthcare provider about all nutritional supplements, vitamins, and herbal products they are taking. It is important to discuss all concurrent supplements with a healthcare provider for proper risk assessment.


Q: Is it normal for Amijeksin to cause mild headaches when you first start?

A: Yes, regulatory documents list headaches as a very common side effect, meaning they are experienced by a high percentage of people taking the medicine. While the exact timing is not specified, it is a frequently reported reaction.


Q: What should I do if a side effect from Amijeksin feels very bothersome?

A: Official patient counseling states that if a symptom or side effect is severe, persistent, or causes you concern, you should contact a healthcare professional immediately. Patients should seek immediate medical attention if they experience signs of serious reactions, such as hearing changes, ringing in the ears, or symptoms associated with kidney problems.


Q: Are there any long-term health risks associated with taking Amijeksin?

A: Prolonged therapy with Amijeksin is associated with an increased potential for serious, sometimes irreversible, side effects. Regulatory warnings highlight the risk of neurotoxicity, ototoxicity (damage to hearing and balance), and nephrotoxicity (kidney damage) with extended use.


Q: Can Amijeksin cause tiredness or dizziness?

A: Official safety documents list dizziness as a common side effect of Amijeksin. Tiredness or fatigue is not generally listed as a common side effect, though unusual weakness should be reported to a healthcare provider, as it may be a symptom of a more serious adverse reaction.


Q: Can Amijeksin affect birth control pills?

A: As a general practice when taking antimicrobial agents, there is a theoretical possibility that they could reduce the effectiveness of estrogen-containing contraceptives. Patients using estrogen-containing contraceptives should discuss the need for alternative methods with their healthcare provider during treatment.


Q: What happens if I miss a dose of Amijeksin?

A: Patient instructions generally advise that a missed dose be taken as soon as it is remembered. However, if multiple doses are missed, contact the prescribing healthcare provider for specific guidance, as noted in the patient instructions.


Q: Is it normal to have vivid dreams or sleep changes while on Amijeksin?

A: Official adverse reaction data lists insomnia, or difficulty sleeping, as a common side effect of Amijeksin, which is a type of sleep change. Vivid dreams are not explicitly detailed in the product information.


Q: Can taking Amijeksin impact my liver function test results?

A: Yes, official safety information documents that elevated liver enzymes (such as AST/ALT) are an uncommon, but possible, side effect of Amijeksin. These elevated values are usually monitored through liver function blood tests.


Q: Why is Amijeksin sometimes prescribed instead of other treatments?

A: Amijeksin is a highly potent antibiotic that is typically reserved for serious infections caused by susceptible bacteria. Regulatory indications highlight its use against Gram-negative bacteria that have demonstrated resistance to other, older antibiotics.


Q: Can I drive or operate machinery while taking Amijeksin?

A: Official product warnings advise against driving or operating heavy machinery if you experience side effects such as dizziness or vertigo. These effects could impair your ability to perform such tasks safely.


Q: Is Amijeksin used to prevent a condition, or only to treat it?

A: Regulatory documents indicate that Amijeksin is indicated specifically for the treatment of severe bacterial infections. Its official use is not generally for the prevention of conditions.


Q: Can men and women take Amijeksin for the same conditions?

A: Yes, official indications for Amijeksin are based on the type of susceptible bacterial infection being treated, regardless of the patient's sex.


Q: Are there any specific lifestyle changes recommended while taking Amijeksin?

A: Patient counseling often highlights the importance of staying well-hydrated during treatment. This measure is generally advised, as it may help mitigate the risk of potential kidney damage (nephrotoxicity).


Q: Is Amijeksin a strong or potent drug?

A: Yes, official quick facts and regulatory documents characterize Amijeksin as a highly potent, semisynthetic antibiotic. This potency is why it is often reserved for serious systemic bacterial infections.


Q: Can Amijeksin be crushed or split if it's a tablet?

A: Amijeksin is supplied as a sterile solution intended for injection or infusion, not as an oral tablet. Therefore, the concern regarding crushing or splitting is not applicable to the approved dosage form of this medicine.


Q: What's the difference in how Amijeksin works compared to other treatment options?

A: Amijeksin belongs to the aminoglycoside class, which provides a fast, bactericidal action. Its mechanism differs from many other antibiotic classes by specifically targeting and disrupting protein synthesis at the bacterial 30S ribosome, rather than only inhibiting cell wall formation.


Q: Is it safe to take Amijeksin if I have a history of heart problems?

A: Amijeksin is associated with potential side effects such as electrolyte imbalances and neuromuscular effects. Patients with any pre-existing medical conditions, including heart problems, are generally treated with close monitoring by their healthcare provider.


Q: Does Amijeksin make you feel sleepy during the day?

A: Sleepiness or fatigue is not listed as a common side effect in official documents, though insomnia is. If unusual tiredness occurs, a healthcare provider should be informed, as this may be a symptom of a more serious issue.


Q: Does Amijeksin interact with common cold or flu medications?

A: Amijeksin has no known major interactions with some common over-the-counter cold/flu ingredients like paracetamol (acetaminophen). Patients are advised to inform their doctor of all over-the-counter products they are taking.

How should Amijeksin be stored and disposed of?

How to Store and Dispose of Amijeksin

The storage and disposal of Amijeksin (Amikacin Sulfate Injection) must comply strictly with official regulatory requirements to maintain product stability and safety.

Storage Conditions

The unopened medicine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is essential to protect the solution from freezing and excessive heat. For child safety, the medicine must be stored out of the sight and reach of children at all times.

Stability and Disposal

Amijeksin is designed as a single-use product. Any unused solution remaining in the vial or ampoule after the required dose is prepared must be discarded. If the solution is diluted for intravenous use, it should be used immediately, with a maximum allowable storage period of 24 hours after preparation. Unused or expired medicine must not be thrown away with household waste or disposed of via wastewater; proper disposal must follow local regulatory instructions, typically through a pharmacist or designated take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amijeksin found in:

A-Z Index: